Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Rating of “Hold” from Brokerages

Fulgent Genetics, Inc. (NASDAQ:FLGT) has been assigned a consensus recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of analysts recently weighed in on FLGT shares. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Fulgent Genetics Price Performance

Shares of NASDAQ:FLGT opened at $15.59 on Friday. The company’s fifty day moving average price is $20.84 and its 200-day moving average price is $23.92. The firm has a market capitalization of $486.89 million, a price-to-earnings ratio of -7.95 and a beta of 0.94. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, February 27th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14. The company had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, equities research analysts expect that Fulgent Genetics will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Amundi grew its stake in shares of Fulgent Genetics by 289.2% in the first quarter. Amundi now owns 34,316 shares of the company’s stock worth $583,000 after purchasing an additional 25,500 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Fulgent Genetics by 28.7% during the first quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock valued at $3,428,000 after buying an additional 45,279 shares during the period. Geode Capital Management LLC raised its holdings in shares of Fulgent Genetics by 1.6% during the second quarter. Geode Capital Management LLC now owns 513,343 shares of the company’s stock valued at $10,207,000 after acquiring an additional 8,105 shares in the last quarter. Creative Planning raised its holdings in shares of Fulgent Genetics by 146.2% during the second quarter. Creative Planning now owns 40,021 shares of the company’s stock valued at $796,000 after acquiring an additional 23,766 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Fulgent Genetics by 14.1% in the second quarter. Legal & General Group Plc now owns 21,025 shares of the company’s stock worth $418,000 after acquiring an additional 2,599 shares during the period. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.